Supplementary Data S1 from HER2 Heterogeneous Breast Cancer Models Reveal Novel Therapeutic Targets and Subclonal Dynamics during Evolution to Resistance to HER2-Targeted Therapies
Authors:Marie-Anne Goyette, Christopher Graser, Marco Seehawer et al.
Supplementary Figure 9 from Targeting the NAD<sup>+</sup> Salvage Pathway Blocks Metabolic Recovery and Enhances β-Lapachone Toxicity in NQO1-Expressing Glioblastoma Cells
Bruce Chang-Gu, Tuvshintugs Baljinnyam et al. - Unknown
Supplementary Figure S4 from <i>SPEN</i> Loss Drives Extrafollicular Diffuse Large B-cell Lymphoma with Female-Specific Lethality and Therapeutic Vulnerabilities
Supplementary Data 2 from First-In-Human Trial of Encapsulated Cells Constitutively Expressing Localized IL2 in Patients with High-Grade Serous Ovarian Carcinoma
Helen D. Clark, Samira Aghlara-Fotovat et al. - Unknown